LifeTech Capital Maintains Strong Buy on Oculus Innovative Sciences

LifeTech Capital is out with its report today on Oculus Innovative Sciences OCLS, maintaining Strong Buy. In a note to clients, LifeTech Capital writes, "We believe shares of Oculus Innovative Sciences are undervalued and are maintaining Oculus with a Strong Buy rating and a 12-18 month Price Target of $4.75. Our valuation is based on a 35x multiple on projected fiscal year 2014 EPS and discounted 15% for cumulative risk." Shares of OCLS closed Friday at $1.72.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorAnalyst RatingsHealth CareLifeTech CapitalOculus Innovative SciencesPharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!